MRVI * Stock Overview
A life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Maravai LifeSciences Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$85.00 |
| 52 Week High | US$85.00 |
| 52 Week Low | US$81.00 |
| Beta | -0.19 |
| 1 Month Change | 0% |
| 3 Month Change | 4.94% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -74.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRVI * | MX Life Sciences | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how MRVI * performed against the MX Life Sciences industry.
Return vs Market: Insufficient data to determine how MRVI * performed against the MX Market.
Price Volatility
| MRVI * volatility | |
|---|---|
| MRVI * Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: MRVI * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MRVI *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 670 | Trey Martin | www.maravai.com |
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing.
Maravai LifeSciences Holdings, Inc. Fundamentals Summary
| MRVI * fundamental statistics | |
|---|---|
| Market cap | Mex$35.96b |
| Earnings (TTM) | -Mex$2.04b |
| Revenue (TTM) | Mex$4.95b |
3.8x
P/S Ratio-9.3x
P/E RatioIs MRVI * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRVI * income statement (TTM) | |
|---|---|
| Revenue | US$288.95m |
| Cost of Revenue | US$148.74m |
| Gross Profit | US$140.20m |
| Other Expenses | US$259.23m |
| Earnings | -US$119.03m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 48.52% |
| Net Profit Margin | -41.19% |
| Debt/Equity Ratio | 68.9% |
How did MRVI * perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/25 14:49 |
| End of Day Share Price | 2023/11/28 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Maravai LifeSciences Holdings, Inc. is covered by 17 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Michael Ryskin | BofA Global Research |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |